Aug 15,2017

Nemaura Signs Heads of Terms for sugarBEAT® with Device Technologies for Australia and New Zealand

Nemaura Medical Inc., a medical technology company focused on the development and commercialization of sugarBEAT® announced today it has signed a non-binding term sheet with Device Technologies for exclusive rights to market and sell sugarBEAT® in Australia and New Zealand. Nemaura Medical expect to launch in Australia and New Zealand in 2018, following an anticipated initial launch in UK in 2017.

COLLABORATION PARTNERSHIP

#institution

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 15,2017

Tandem Diabetes Care Begins Enrollment in Pivotal Trial for First Touchscreen Insulin Pump with Predictive Low Glucose Suspend (PLGS)

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced enrollment of the first patients in an at-home pivotal trial for its t:slim X2™ Insulin Pump using Tandem's predictive low glucose suspend (PLGS) technology. The insulin pump system, which uses an integrated Dexcom G5® Mobile Continuous Glucose Monitor (CGM), is designed to suspend insulin delivery when low blood glucose is predicted and subsequently resume insulin delivery when glucose levels begin to rise.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Aug 22,2017

Brighter's main patent has been approved by United States Patent and Trademark Office

The US patent authority has granted Brighter's main patent in the US, which includes Actiste and its unique ability to integrate all functions in the patient's activity chain in one and the same device, i.e. to measure and analyze a biomarker (e.g. blood glucose), as well as inject medicine (e.g. .eg insulin).

PRODUCT

#bgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Aug 23,2017

DarioHealth Closes on $5 Million Through Private Placement Offerings

DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health Company with mobile health and big data solutions, announced today that it has closed on concurrent private placement offerings with domestic and non-U.S. investors for the sale of shares of the Company's common stock and shares of the Company's newly designated Series B Convertible Preferred Stock in concurrent private placement offerings. As a part of these private placement transactions, which totals $5 million in the aggregate before expenses and placement agent fees, the Company issued 483,333 shares of common stock at a price per share of $1.80 and 2,307,654 shares of Series B Convertible Preferred Stock at a price per share of $1.80. Investors in the offering included existing investors, as well as new investors including SC Fundamental Value Fund, L.P. and Pegasus Capital II, L.P.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Aug 23,2017

Tandem Diabetes Care Announces Launch of t:lock Connector for its Insulin Pump Cartridges and Infusion Sets

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) today announced the launch of the t:lock™ Connector for its insulin pump cartridges and infusion sets. All of the infusion sets currently offered by the Company will be made available with the new t:lock Connector, produced and supplied by Unomedical a/s, a ConvaTec Group Plc company.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Aug 24,2017

Tandem Diabetes Care Announces Issuance of Patent Related to Remote Bolus Feature for Medical Infusion Pumps

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) today announced the issuance of U.S. Patent No. 9,737,656 titled "Integration of Infusion Pump with Remote Electronic Device". The patent generally relates to using a software application operating on a remote consumer electronic device to initiate, program and deliver a medicament bolus to a patient using a medical infusion pump where the pump provides an indication of the bolus, such as by an audible or vibration alert.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Aug 25,2017

One Drop Reports Dramatic A1c Reduction Among People With Diabetes Using One Drop Mobile App

One Drop today announced the results of a retrospective study of people with diabetes (type 1 and type 2) using the One Drop | Mobile diabetes management app, demonstrating a 1.1% to 1.3% absolute reduction in A1C in just 4 months. The results were published yesterday, August 24, 2017, in JMIR Diabetes.

CLINICAL STUDY

#mobile app

#bgm

View Analyst & Ambassador Comments
Go to original news
Aug 25,2017

Brighter Half-year report 2017

Brighter shared its half-yearly report in 2017, stating that its perating income amounted to SEK 21,475 thousand, compared to SEK 12,687 thousand the same period last year.

View Analyst & Ambassador Comments
Go to original news
Aug 28,2017

Tandem Diabetes Care Announces FDA Approval and Launch of t:slim X2 Insulin Pump with Dexcom G5 Mobile CGM Integration

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced U.S. Food and Drug Administration (FDA) approval and commercial launch of the t:slim X2™ Insulin Pump with Dexcom G5® Mobile continuous glucose monitoring (CGM) integration, the first sensor-augmented insulin pump approved to let users make treatment decisions without pricking their finger. The software featured on this pump will also be available to current t:slim X2 Pump users at no cost via remote software update, allowing them to add CGM integration to their existing pumps from home using a personal computer. Individual emails are being sent directly to t:slim X2 Pump customers with instructions on how to perform the update. The t:slim X2 Pump with Dexcom G5 Mobile CGM integration is approved for ages 6 and older.

REGULATORY FDA

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 29,2017

Nemaura Develops Medical Grade SugarBEAT® Android App for Diabetes Management

Nemaura Medical Inc. (OTCQB: NMRD), a medical technology company focused on the development and commercialization of sugarBEAT®, a wireless adhesive skin-patch for adjunctive use by diabetics as a non-invasive and needle-free continuous glucose monitoring (CGM) system announced today that it has completed development of a medical grade app prepared and verified in accordance with ISO13485 quality systems and the appropriate medical devices directives, and designed to be used with the sugarBEAT® device or with glucose meters and strips to display glucose levels on users android mobile devices.

PRODUCT

#mobile app

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES